#United States #San Diego #Neurocrine Biosciences #INGREZZA #Eiry W. Roberts

Neurocrine Biosciences Welcomes Back Dr. Eiry W. Roberts as CMO

In a significant leadership change, Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Dr. Eiry W. Roberts has been reappointed as the Chief Medical Officer (CMO). This decision comes after a mutually agreed departure of Sanjay Keswani, M.D. Dr. Roberts' return to this pivotal role is anticipated to bring invaluable continuity and expertise as Neurocrine advances its clinical development plans.

Dr. Roberts previously held the CMO position from 2018 until 2025 and has remained connected to Neurocrine as a Strategic Advisor since then. Her extensive experience includes spearheading significant efforts that led to the FDA approval of treatments such as INGREZZA® and the innovative crinecerfont development program, which were critical to meeting the needs of patients with serious conditions.

Before joining Neurocrine, Dr. Roberts dedicated 26 years to Eli Lilly and Company, where she ascended to the role of Vice President, Research and Development. Her tenure at Eli Lilly equipped her with a rich background in both research and clinical development, which positions her to contribute effectively to Neurocrine’s ambitious objectives. Beyond her corporate engagements, Dr. Roberts also influences the pharmaceutical landscape as a member of the Board of Directors for Bausch Health Companies and previously for Amicus Therapeutics until its acquisition by BioMarin Pharmaceutical in 2026.

Kyle W. Gano, Ph.D., the President and CEO of Neurocrine, expressed enthusiasm about Dr. Roberts' return, stating, "Her deep knowledge of Neurocrine, our pipeline, and our clinical development programs provides strong continuity at a time when we are advancing multiple late-stage programs and preparing for several important clinical milestones." This critical leadership transition is expected to ensure a smooth progression of ongoing initiatives and maintain the momentum of Neurocrine's robust clinical portfolio.

In her new role, Dr. Roberts is focused on alleviating suffering for patients with unmet medical needs. Her statement reflects a commitment to driving the company’s mission forward: "I am honored to assume the Chief Medical Officer role again and contribute to our mission of relieving suffering for people with unmet needs. Having remained closely connected to the Company as a Strategic Advisor, I am excited about the opportunities ahead. I look forward to building on the teams' progress, advancing the portfolio, and ultimately delivering meaningful benefits for patients and value for shareholders."

Neurocrine Biosciences is a biopharmaceutical powerhouse committed to developing transformative treatments for conditions affecting neurological, psychiatric, endocrine, and immunological health. Their diverse portfolio includes FDA-approved therapies for conditions such as tardive dyskinesia and chorea associated with Huntington's disease, as well as promising pipelines in advanced clinical stages aimed at addressing significant healthcare challenges.

The company takes pride in its dedication to applying profound insights into neuroscience to tackle complex health issues. Neurocrine’s commitment to brave science promises continuous efforts in discovering effective medicines, reinforcing their responsibility to both patients and investors.

To keep informed about the developments and ongoing initiatives at Neurocrine, stakeholders are encouraged to visit the company’s website at neurocrine.com and follow their updates on platforms such as LinkedIn, X, Facebook, and YouTube.

Conclusion

As Neurocrine Biosciences prepares for significant clinical milestones, Dr. Eiry W. Roberts' return as Chief Medical Officer underscores the company's strategic focus on continuity and expertise. With her leadership, Neurocrine is positioned to advance its impactful programs and further its mission to relieve patient suffering. The pharmaceutical industry is poised to witness the evolution of Neurocrine under Dr. Roberts' guidance, as the organization steadfastly pursues innovations in patient care.